Table 4.

Association of female menopausal hormone use with endometrial cancer among women age ≥40 years, 1995–2013a

Age adjustedbMultivariable adjustedc
ExposureCasesPerson-yearsRatedIRR95% CIIRR95% CI
Estrogen-only FMH usee
 Neverf155277,47155.91.00Referent1.00Referent
 Ever1612,130131.91.280.76–2.171.320.78–2.23
  Former98,882101.30.860.44–1.700.870.44–1.72
   Years since last use
    1–956,23080.30.710.29–1.730.730.30–1.80
    ≥1042,637151.71.190.43–3.261.150.42–3.17
  Current73,248215.53.451.56–7.653.781.69–8.43
  Duration (years)
   1–41310,668121.91.220.68–2.161.250.70–2.23
   ≥531,271236.01.850.58–5.891.900.59–6.09
Estrogen + progestin FMH useg
 Neverf155277,47155.91.00Referent1.00Referent
 Ever2528.60287.40.710.46–1.110.820.53–1.28
  Former1517,79084.30.550.32–0.960.630.36–1.09
   Years since last use
    1–9913,58666.20.460.23–0.920.530.27–1.06
    ≥1064,180143.50.790.34–1.830.860.37–2.01
  Current1010,81292.51.290.65–2.561.550.78–3.11
  Duration
   1–41620,35678.60.710.42–1.200.790.47–1.35
   ≥597,304123.20.810.41–1.610.990.49–1.98
 Pattern of progestin useg
  Never used FMHf177186,11395.11.00Referent1.00Referent
   <2 wk/mo.117,836140.41.140.62–2.111.290.70–2.39
   2–3 wk/mo.05,0800.00.000.00
   Continuous89,44284.70.640.31–1.310.740.36–1.50
   Other11,39071.90.620.09–4.440.630.09–4.49
Progestin-only FMH usee,g
 Neverf155277,47155.91.00Referent1.00Referent
 Ever87,366108.61.740.85–3.561.510.73–3.09
  • aAnalysis restricted to women ≥40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of multiple FMH types.

  • bAge-adjusted model stratified by age and study period.

  • cMultivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking, BMI, and vigorous physical activity.

  • dCrude rate per 100,000 person-years.

  • eAdditionally adjusted for estrogen plus progestin FMH use.

  • fNever reported any FMH use.

  • gAdditionally adjusted for estrogen-only FMH use.